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Adherence to HAART: Africans Take 
Medicines More Faithfully than North 
Americans
Amir Attaran
In 2001, the chief of the United States Agency for International 
Development (USAID), Andrew Natsios, gave this justiﬁ  cation 
to the US Congress for why the agency opposed giving 
antiretroviral therapy (ART) to Africans with HIV:
“If we had [HIV medicines for Africa] today, we could 
not distribute them. We could not administer the program 
because we do not have the doctors, we do not have the 
roads, we do not have the cold chain...[Africans] do not know 
what watches and clocks are. They do not use western means 
for telling time. They use the sun. These drugs have to be 
administered during a certain sequence of time during the 
day and when you say take it at 10:00, people will say what do 
you mean by 10:00?” [1].
Natsios was not the only policy maker to justify 
withholding ART from Africans on the basis that weak 
infrastructure, or patients’ inability to take tablets, 
would stymie adherence. Senior ofﬁ  cials of the World 
Bank and Thai government said in The Lancet: “[ART] is 
not...a technology that most poor people could adhere 
to...[Further] The use of public funds to subsidise the 
treatment of patients in the poorest countries who are most 
able to comply...would be highly inequitable” [2].
Two new systematic reviews prove these speculations 
were mistaken [3,4]. Despite their continent’s poverty, 
and schooled or not in time keeping, Africans overcome 
these barriers and are better than North Americans at 
taking ART. These studies correct the misconception of 
earlier, nonsystematic reviews that concluded that Africans’ 
adherence to medicines is “often poor” [5].
The ﬁ  rst review (which I coauthored) identiﬁ  ed 31 
studies from North America and 27 from sub-Saharan Africa 
examining adherence to ART [3]. The bottom line was 
simple: using the customary deﬁ  nition that “good adherence” 
means taking ART as prescribed 95% of the time or more, 
then 82% of Africans succeeded at that goal, compared with 
only 55% of North Americans (p is less than 0.001). 
Some may see this result as surprising. To live in Nairobi 
means to face so many privations compared to New York 
that to overcome them and excel seems almost storybook 
untrue. But privation can cut both ways. People who have 
been denied the necessities of life, who then receive the gift 
of medicines and a chance to live, may be more likely to 
appreciate ART. 
Although Africans take ART more faithfully that North 
Americans, there is room for improvement. Here is where 
the second review is instructive [4]. The authors identiﬁ  ed 
84 studies from rich and poor countries that qualitatively 
or quantitatively identiﬁ  ed factors impeding or facilitating 
adherence to ART. The impeding factors in rich and 
poor countries were familiar ones: patients’ aversion or 
forgetfulness about medicines; lack of trust in health workers; 
fears about AIDS or its treatment; and emotions of isolation. 
The authors found only two qualitative studies of barriers 
and facilitators of adherence among patients in poor 
countries [4]. There are accordingly few data on which to 
conclude that, for example, patients must give up alcohol, 
or must undergo directly observed therapy, to adhere to 
medicines, as some programs require [6,7]. Such measures 
may indeed be unnecessary.
In rich countries, the study failed to identify any obvious 
“big ﬁ  x” that could turn non-adherent patients into adherent 
ones. On the other hand, for developing countries, “ﬁ  nancial 
constraints” towered above the other reasons why poor 
patients may fail to adhere to ART. That is cruelly ironic, 
because the same international development policy makers 
who rejected the idea that poor people could adhere to ART 
also worked for ﬁ  nancial donors such as USAID and the 
World Bank, and their passionate arguments against ART 
stalled the delivery of the one variable that helps adherence—
money.
Where is the ﬂ  aw that allowed speculation to get ahead of 
evidence in development policy making, and to reach the 
baseless conclusion that Africans could not adhere to ART, 
or needed to be commanded paternalistically (e.g., “you 
must abstain from alcohol”) to adhere to ART, when no such 
conclusion would be reached for rich people? More to the 
point, how can one recognize when a particular development 
policy is so baseless and speculative, the better to abandon it? 
A serviceable answer, I believe, is that one should be highly 
suspicious whenever development policy makers sound 
dismissive of the people whom they are hired to help. The 
central aspiration of development work is helping the poor 
and sick become richer and healthier. Such an aspiration 
is incompatible with speculating that certain foreigners are 
incapable of enjoying the fruits of development. I believe that 
the views of Natsios and the World Bank and Thai ofﬁ  cials, 
speculating that Africans could not adhere to ART, were 
dismissive in just this way. 
Dismissing patients in this way leads to a lower standard of 
medical care. The medical establishment is more sensitive to 
the standard of care than is the development establishment, 
and so the medical establishment must be vigilant—and 
vocal—against bad development policy. Development 
policymakers have also freely opined that Africans could not 
manage to take artemisinin-based combination therapies 
for malaria, or second-line treatments for tuberculosis. We 
now know that Africans are capable of all these things—but 
overcoming the dismissals and excuses took years, during 
which millions died.  
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“The Right Stuff”: The Global Burden 
of Disease
Bolajoko O. Olusanya
PLoS Medicine is one of the few journals with a dedicated 
forum for neglected diseases, and the suggestion by its editors 
that journals should give preference to diseases based on 
their relative contributions to the global burden of disease 
is noteworthy as a positive step towards optimising the 
global research agenda [1]. Undoubtedly, the recent report 
by Mathers and Loncar, like earlier versions of the Global 
Burden of Disease (GBD) study, represents the best effort 
yet at providing a level playing ﬁ  eld for diverse diseases and 
health conditions globally [2]. A key feature of this project 
is the evaluation of health outcomes in terms of mortality 
and burden of disease indexed by disability-adjusted life 
years (DALYs). However, a few concerns still linger on 
the application and current scope of the study which have 
signiﬁ  cant implications for health-care policy, particularly in 
the developing world. 
The concept of the “burden of disease” was introduced 
to redress the inequality and inequity occasioned by the 
exclusive use of mortality as the summary measure of 
population health [3,4]. The DALY was thus intended to 
provide information on non-fatal health outcomes of diseases 
that have been largely neglected in health planning because 
of the “conceptual and deﬁ  nitional complexity of measuring 
morbidity and disability in populations” [5]. However, it 
is uncertain how far the well-intentioned paradigm shift 
in disease evaluation has been achieved, as global health 
initiatives are still rarely concerned with reduction in “burden 
of disease” besides mortality. This is also applicable to 
health planning at country or community level. In fact, the 
signiﬁ  cance of noncommunicable/chronic health conditions 
such as cardiovascular diseases, cancer, diabetes, and mental 
illness is still being predominantly promoted on the basis 
of case fatality rather than disease burden. Conceptually, 
DALY and its variants like quality-adjusted life years (QALYs) 
represent equitable measures of population health that 
should be more actively promoted, but more work is required 
to address some of the methodological and equity concerns 
that have been raised since their introduction to global health 
[6,7].
The continued ranking of childhood diseases alongside 
adult diseases in the GBD report often portrays children 
as “young adults”. This practice distracts from diseases and 
conditions that have signiﬁ  cant impacts on optimal early 
childhood development. Moreover, the risk of death for 
children younger than ﬁ  ve years is projected to fall by more 
than 40% between 2005 and 2030, while life expectancy 
globally is expected to improve signiﬁ  cantly by 2030, with the 
largest increases occurring in Africa and South Asia [1]. This 
trend is likely to bring to the fore the neglected discourse on 
the quality of life for the many survivors of acute childhood 
illnesses, particularly as the years lived with disability for 
chronic diseases of childhood onset far exceed those of adult 
onset. For instance, it is difﬁ  cult to justify the continued 
failure to address a highly preventable perinatal condition 
such as neonatal jaundice, which may not be a leading cause 
of mortality but currently causes substantial burden in low-
income countries [8]. 
Similarly, hearing loss of adult onset remains one of the 
ten leading causes of DALYs globally, particularly in high-
income and middle-income countries, but is not expected 
to be a leading health problem in low-income countries 
by 2030 [1]. While this is gratifying to note, the current 
trend in the prevalence of disabling hearing loss (which 
more than doubled from 120 million in 1995 to about 
278 million persons in 2005, two-thirds of whom reside in 
developing countries) may have much greater impact than 
projected, considering the envisaged improvement in life 
expectancy [9]. But more importantly, the exclusion of 
hearing loss of childhood onset or the failure to adequately 
account for permanent childhood hearing loss in these 
projections underrepresents the true burden of hearing loss. 
It disfranchises about 718,000 babies born annually in the 
developing world with neonatal hearing loss from available 
time-bound early detection and intervention services now a 
standard of neonatal care in developed countries [10]. 
The call by Mathers and Loncar for more robust studies 
across the regions of the world must not be overlooked or 
considered lightly. As new evidence emerges from such 
studies, the projected trend and ranking in many countries 
may ultimately differ from the overall global and regional 
picture in the current GBD report. Meanwhile, systematic 
steps to address these and other concerns should be 
considered urgently to effectively promote the concept of the 
burden of disease. Invariably, we all need to be guided by a 
variety of sources and perspectives in determining “the right 
stuff” for the heterogeneous populations of the world.  
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Gut Mucosa in HIV Infection: “Immune 
Milk” Solution
Shawn J. Green
In recent weeks, three noteworthy papers, published in PLoS 
Medicine, The Journal of Virology, and Nature Medicine, direct 
our attention to the gut as a critical target in HIV-1 infection 
and portal for therapeutic intervention.
In PLoS Medicine, Mehandru and colleagues report that 
over half of the CD4+ T cells in the gut mucosa are lost 
within the ﬁ  rst few weeks after HIV-1 infection and remain 
consistently low, compared to peripheral blood sources, 
despite long term antiretroviral therapy; furthermore, of the 
few CD4+ T cells that persist in the gut, a signiﬁ  cant increase 
in immune activation is observed [1]. Consistent with earlier 
observation in SIV models, Veazey reminds us that the battle 
against HIV-1 should focus on the intestinal mucosa with 
therapeutic strategies to reduce gut immune activation [2]. 
The longitudinal study in The Journal of Virology by 
Guadalupe and colleagues showed a similar discordance 
in CD4+ T cells between restoration in peripheral blood 
and signiﬁ  cant delay in the gut mucosa of chronic infected 
individuals during antiretroviral therapy. Here, the depletion 
in CD4+ T cells was associated with an increase in gut immune 
activation, CD8+ T cells, and associated inﬂ  ammation with 
a corresponding decease in epithelial growth and repair-
associated genes in gut mucosal tissue [3]. Brenchley and 
colleagues suggest in Nature Medicine that HIV infection 
causes this breakdown in the gut mucosa resulting in a “leaky 
gut,” thus allowing translocation of gut-derived endotoxin 
and the subsequent triggering of immune activation [4]. 
Collectively, these observations suggest that an orally active 
therapeutic, used in conjunction with antiretroviral therapy, 
be designed to both block gut-derived microbial translocation 
and stimulate restitution of the gut epithelium. The hope 
would be to restore immunological integrity of the intestinal 
mucosal barrier, thereby controlling immune activation, both 
locally, in the gut mucosa, and systemically by suppressing 
cellular targets distal to the gut that may directly contribute to 
the progression of AIDS [5–8]. 
The design for such an orally active therapeutic may 
be found in the complex formula of bovine colostrum 
and “immune milk,” which has long been recognized to 
offer passive protection from a broad number of enteric 
bacterial and viral pathogens, primarily via the transfer 
of immunoglobulins and suppression of gut-associated 
inﬂ  ammation with promotion of mucosal repair and 
regeneration. 
The gut in chronic HIV-1-infected individuals appears to be 
reminiscent of newborn calves. Calves are born with a highly 
immature mucosal immune system and “leaky gut”  which, if 
not immediately corrected, results in death due to infection 
and associated systemic immune activation. However, the 
cow’s ﬁ  rst milk rescues her calves from harmful gut microbes 
with a uniquely complex cocktail enriched with neutralizing 
polyclonal antibodies, cytokine tissue repair factors, and 
immune enhancing probiotics, such as Lactobacillus species. 
Regular consumption of biologically active bovine 
colostrum has been known for years to promote the 
development of infantile gut-associated lymphoid tissue 
and enhance CD4+ levels, while suppressing CD8+ and 
inﬂ  ammatory bowl disease (IBD), including ulcerative colitis 
and Crohn disease [5]. The severity of IBD is often correlated 
with gut microbial-endotoxin translocation, which now 
appears in chronic HIV-1-infected individuals [4]. Similar to 
bovine colostrum, “immune milk” from properly vaccinated 
cows affords passive immunity against bacterial, viral, and 
fungal infections in the human gastrointestinal tract, as well 
as taming gut inﬂ  ammation [8]. 
Hence, there may be lessons learned from Bessie’s 
“immune milk.” If viewed as a unique formula that has 
evolved to complement gut immunity, “immune milk” may 
also provide relief in chronic HIV-infected individuals. Initial 
studies have already shown that ingestion of colostrum 
alleviates refractory diarrhea in HIV patients with a 
corresponding increase in both body weight and peripheral 
blood CD4+ T cells [9,10]. As we learn more about the gut 
microenvironment in HIV-infected individuals, Bessie may 
prove to be a worthwhile platform for the consideration 
of “immune milk” exhibiting both microbial endotoxin 
and HIV-neutralizing activity along with its innate anti-
inﬂ  ammatory and tissue repair and regenerative properties.  
Shawn J. Green (shawng@origobiosciences.com)
Origo Biosciences
Davis, California, United States of America
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Educating Health Professionals 
about Drug and Device Promotion: 
A Nepalese Perspective
P. Ravi Shankar
I read with interest the article by Mansﬁ  eld et al. regarding 
educating health professionals about drug and device 
promotion [1]. Teaching about drug promotion is becoming 
increasingly important here in Nepal. During their 
pharmacology training at the Manipal College of Medical 
Sciences, Pokhara, medical students are taught to critically 
analyze drug advertisements and other promotional material 
against the World Health Organization’s ethical criteria for 
medicinal drug promotion [2]. Their abilities in the critical 
analysis of drug promotional materials are evaluated during 
the pharmacology practical examination. The students are 
also taught to critically evaluate drug promotion by medical 
representatives (MRs) using the medium of role-play [3].
The four recommendations made by the authors are 
important, but developing countries may face problems 
in their implementation. We recommend that all health 
professionals be educated about decision making and 
evaluation of evidence and promotion. Our department runs 
a drug information center in the teaching hospital and we are 
trying to use this center to promote evidence-based medicine. 
However, there are no formal courses on evaluating the 
evidence. Doctors do not have an adequate knowledge of 
statistics to arrive at evidence-based decisions.
The authors’ second and third recommendations pose 
further problems. Conferences in Nepal continue to be 
heavily sponsored by the pharmaceutical industry. MRs have 
unrestricted access to doctors in our hospital and in most 
other hospitals in Nepal. One-to-one visits, personal gifts, 
and other methods of sponsorship are the norm. Academic 
detailing is absent. I am personally ambivalent about banning 
one-to-one detailing. Many health professionals in South 
Asia are in private practice or work in small hospitals. It is 
an unfortunate fact, but MRs may be their only source of 
information about medicines. Banning MRs may deprive 
them of this source, however biased it may be. Exposing 
students to misleading presentation, fostering false beliefs, 
debunking these beliefs, and explaining the misleading 
techniques is an effective approach, used in our department 
during teaching critical evaluation of medicinal drug 
promotion. 
We have had mixed success regarding educating health 
professionals to avoid promotion or look at it critically. 
We have been able to inﬂ  uence students during the ﬁ  rst 
two years of their training. The inﬂ  uence of our training is 
considerably eroded once students are in their clinical phase. 
Enlisting the support of clinicians, making them aware of 
irrational promotion, and using their services to teach doctors 
in training is vital if we are to make progress. Education 
regarding the most reliable sources of information is lacking 
in South Asia. Health organizations, professional associations, 
and other bodies should develop information sources which 
are readily accessible to prescribers. Western information 
sources may have many limitations in developing countries.
So far, no medical student organizations in Nepal have taken 
up the issue of pharmaceutical promotion. The curriculum 
of Kathmandu University recommends teaching students to 
assess promotional materials. However, many medical schools 
do not address this vital issue. Meanwhile, the Nepalese 
pharmaceutical industry is coming of age. The pharmaceutical 
giants based in our Southern neighbor, India, are also active 
in Nepal. It is time for medical professionals to get their act 
together to ensure a proper relationship with the industry.  
P. Ravi Shankar (ravi.dr.shankar@gmail.com)
Manipal College of Medical Sciences
Pokhara, Nepal
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Educating Health Professionals about Drug and Device 
Promotion: Authors’ Reply
We thank Prof. Ravi Shankar for his thoughtful reﬂ  ections 
[1] on our recommendations for education about drug 
and device promotion [2]. Prof. Shankar is one of the few 
who have published an evaluation of education about drug 
promotion [3], so we are pleased that he concurs with 
most of our recommendations. We agree with him that 
implementation of our recommendations will be difﬁ  cult. 
The main barrier to implementation is the widespread denial 
by health professionals that we are often adversely inﬂ  uenced 
by promotion. This denial arises partly from ignorance of the 
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evidence about promotion and partly from a refusal to accept 
that evidence, because it is viewed as insulting our self-esteem 
[4]. We believe health professionals need to move from 
overconﬁ  dent illusions of invulnerability to accept that we 
are human, so it is normal for us to be misled by persuasive 
promotional techniques [5]. 
Prof. Shankar seems to believe that doctors can be taught 
to “critically evaluate drug promotion” [1] so as to “optimise 
time spent with medical representatives” [3], although he 
acknowledges only “mixed success” with his medical students 
[1]. By contrast, we are pessimistic that doctors will ever 
be able to gain more good than harm from visits by sales 
representatives in any country. All the relevant evidence of 
which we are aware suggests that exposure to promotion 
correlates with less appropriate prescribing [6]. Furthermore, 
the skills required to avoid being misled may take many years 
to learn, and many hours to apply after each visit. There is no 
proven method for overcoming normal human vulnerabilities 
such as the tendency to believe attractive, socially skilled 
people, especially if they have built up trust over many visits. 
Consequently, we believe the onus is on anyone who claims 
that it is possible for health professionals to learn how to 
gain net beneﬁ  t from sales representatives’ visits to produce 
evidence to support that claim.
Prof. Shankar is ambivalent about our recommendation 
that health professionals avoid promotion because in his 
country, Nepal, sales representatives “may be their only 
source of information about medicines.” We share Shankar’s 
concern about lack of relevant independent information 
for doctors in many countries. In all countries, whoever 
pays for health care will get better results at lower cost by 
funding independent information, rather than paying direct 
and indirect costs from inappropriate drug and device use 
caused by misleading promotion. Payers for health care are 
more likely to fund such initiatives if they understand how 
harmful drug promotion is. Even if no such initiatives are 
forthcoming, we reject the idea that any information—even 
if it is misleading—is better than no information at all. The 
majority of new drugs are more expensive than their older 
analogues, but no better (and sometimes worse). Patients 
would be better off if doctors were ignorant non-prescribers 
of such drugs rather than misinformed frequent prescribers. 
Current patterns of health professionals’ interactions with 
the drug and device industry are causing much harm [6]. Our 
three main tasks are to develop optimal recommendations 
for improvement, identify barriers to implementation, 
and develop methods for overcoming those barriers. We 
appreciate any input, including Prof. Shankar’s reﬂ  ections, 
that will help us improve our performance on those tasks.  
Peter R. Mansﬁ  eld (peter@healthyskepticism.org)
Healthy Skepticism, Incorporated
Willunga, Australia
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Structural Violence and Clinical 
Medicine: Free Infant Formula 
for HIV-Exposed Infants
Ted Greiner, Christophe Grundmann, Katherine 
Krasovec, Christian Pitter, Catherine Wilfert
We wholeheartedly agree with Paul Farmer and colleagues 
[1] that it is vitally important to examine social, as well as 
molecular, causes of disease. Unless we carefully consider 
the full range of factors that underlie a given problem, we 
may produce “solutions” with unintended and deleterious 
consequences. In this light we express our concern about the 
infant feeding approach advocated in their article to reduce 
mother-to-child transmission of HIV in Rwanda. 
While exclusive replacement feeding reduces the risk of 
transmission between HIV-positive mothers and their infants, 
it does not adequately address the specters of infection and 
undernutrition that accompany avoidance of breast-feeding. 
We are convinced—by data from regions that are similar 
to Rwanda and even from African countries with higher 
standards of living—that replacement feeding from birth is 
a dangerous and inappropriate approach for HIV-affected 
families in countries like Rwanda. 
In addition, avoiding breast-feeding from birth can be 
exceedingly risky, particularly in the same regions where 
the risk of mother-to-child transmission of HIV is highest. 
While Partners in Health (PIH) offers high-quality health-
care support and ﬁ  nancial assistance to reduce the risks 
associated with breast-feeding avoidance in two districts in 
Rwanda, it is impossible to eliminate those risks. Researchers 
have found that children in Ghana, Peru, and India who are 
not breast-fed between the ages of six weeks and six months 
have a ten-fold higher risk of death [2]. A multi-country 
analysis by the World Health Organization (WHO) showed 
that infants who were born to mothers with little education 
and were not breast-fed had a ﬁ  ve-fold increased risk of death 
from six to 11 months of age. Since about 5% of breast-fed 
Rwandan babies already die in the ﬁ  rst six months of life 
February 2007  |  Volume 4  |  Issue 2  |  e88  |  e87PLoS Medicine  |  www.plosmedicine.org 0395
and another 3.5% from six to12 months [3], it is essential 
that PIH substantiate the mortality, nutrition, and morbidity 
outcomes resulting from their approach before promoting it 
more widely. 
Given that breast-feeding avoidance increases the risk 
of death from other causes, even as it decreases the risk of 
HIV transmission, is there a net gain? The concept of “HIV-
free survival” combines the likelihood of surviving with the 
likelihood of not becoming HIV infected, allowing a more 
comprehensive assessment of the risks and beneﬁ  ts of infant 
feeding. In Botswana [4] and the Ivory Coast [5], rates of 
HIV-free survival were no better among formula-fed infants 
than among infants breast-fed for three to six months. At 
this year’s WHO Consultation on HIV and Infant Feeding in 
Geneva, reports showed high death rates in ongoing trials in 
Kenya, Uganda, and Malawi associated with breast-feeding 
cessation at three to six months. These results were despite 
earlier assumptions that breast-feeding cessation at this age 
might be safe, while avoiding most of the HIV transmission 
associated with prolonged breast-feeding [6]. Since these 
carefully controlled studies represent best-case scenarios for 
replacement feeding, most actual program settings will favor 
breast-feeding (actually, disfavor replacement feeding). 
The risk of mother-to-child HIV transmission in the ﬁ  rst 
six months in a country like Rwanda, where 81% of women 
are still exclusively breast-feeding at four to six months [3], 
is relatively low—probably approximately 0.3% per month 
[7]. It may be even lower in districts like those in which PIH 
works, where eligible HIV-positive mothers begin receiving 
highly active antiretroviral therapy during pregnancy, because 
the majority of postnatal HIV transmission is from mothers 
with low CD4+ cell counts [8]. 
Scientiﬁ  c evidence amply demonstrates the signiﬁ  cant 
risks that accompany replacement feeding and the safety 
and effectiveness of exclusive breast-feeding for the ﬁ  rst 
six months, and continued breast-feeding thereafter as 
appropriate and safe. Around the world, researchers, 
programmers, and policy makers are becoming increasingly 
convinced that the infant feeding counseling component of 
prevention of mother-to-child transmission of HIV programs 
must focus on optimizing HIV-free survival rates, not simply 
on HIV transmission. Accomplishing this means taking full 
account of all factors, both social and molecular, that are at 
work in a particular context, and tailoring responses to meet 
them.  
Ted Greiner (tgreiner@path.org)
Katherine Krasovec
Program for Appropriate Technology in Health
Seattle, Washington, United States of America
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Blindness Survey Methods: 
Response from Sudan Study Authors
Jeremiah Ngondi, Francis Ole-Sempele, Alice Onsarigo, 
Ibrahim Matende, Samson Baba, Mark Reacher, Fiona 
Matthews, Carol Brayne, Paul M. Emerson
We thank the authors [1,2] for the two perspectives on our 
articles [3,4]. Our study estimated the prevalence of blindness 
in Mankien at 4%, which Kuper and Gilbert describe as being 
“beyond the range” of the studies reviewed by Pascolini et 
al. [5]. The review did not include any studies from the ten 
states that compose southern Sudan. The nearest surveys 
reported were conducted in 1998 in Al-Ginena province of 
Southern Darfur—which is within the 16 northern states 
of Sudan governed from Khartoum, and was not directly 
affected by the war in the south. The Al-Ginena studies show a 
blindness prevalence of 3.2% in all ages [6,7]. Yet despite the 
geographical proximity, two decades of civil war in the south 
were accompanied by the absence of a health infrastructure, 
and no preventive health services to speak of, which makes 
southern Sudan unique. Comparisons with other parts of 
Sudan or with other countries are probably not justiﬁ  ed or 
meaningful.
Our survey was conducted in Mankien, which was 
anecdotally known to be endemic for severe blinding 
trachoma, and this was subsequently conﬁ  rmed by our 
trachoma survey, which showed an overall prevalence of 
trichiasis and bilateral corneal opacity of 9.6% and 3.1%, 
respectively [3]. The prevalence of blinding cataract in 
Mankien was consistent with expectation, and would 
presumably have been higher had there been a systematic 
over-sampling of the blind. It is the prevalence of blinding 
trachoma that sets the population apart from all others 
reported and reviewed by Pascolini et al. These survey 
data from Mankien are extremely valuable in that they 
demonstrate the way uncontrolled trachoma can ravage 
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inaccessible and underserved communities who have, quite 
literally, been off the map until recently. The war affected the 
whole of southern Sudan, and extremely high levels of active 
trachoma and trichiasis have been observed in all the areas 
that we have managed to survey in recent years [8]. Although 
not generalizable to the ten southern states, these data from 
Mankien are probably indicative of the overall situation in 
southern Sudan. 
We acknowledge the survey limitations highlighted 
by Kuper and Gilbert, and have addressed them in the 
discussion. Our sampling methodology has been used in 
similar surveys in Kenya [9], Bangladesh [10], Tehran 
[11], Cameroon [12], and Pakistan [13]. Use of basic eye 
examination technique by auxiliary health-care workers in 
blindness surveys has been suggested for settings without 
ophthalmologists [14], which is entirely consistent with what 
the integrated eye care workers are trained to do. Kuper 
and Gilbert’s difﬁ  culty appears to stem from the ﬁ  ndings, 
rather than the methodology. They offer two interpretations 
to explain the data, whilst not acknowledging the most 
parsimonious explanation, and that is that these data are an 
accurate reﬂ  ection of the situation on the ground; we cannot 
risk not accepting this. The international community must 
rise to the challenge of planning and offering service for 
blindness prevention interventions in these desperately needy 
communities. We should not let an academic argument as to 
whether the prevalence of blindness is really 4% or whether it 
is, perhaps, a little lower be the basis for continued neglect. 
We fully agree with both Kuper and Gilbert, and Buchan 
that there is need for a concerted effort to survey the 
entire region, provide resources, and deliver services to the 
marginalized and poverty stricken communities in southern 
Sudan.  
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